ClinicalTrials.gg

Program

Actinium Ac 225 SSTR2-targeted Agent RYZ401

Its studies are mostly in Gastro-enteropancreatic neuroendocrine tumor, led by Bristol-Myers Squibb.

Furthest: phase 1, since Aug 20, 20251 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 1since Aug 20, 2025Aug 20, 2025Feb 2027phase 1 · NCT07165132
  • Named in Bristol-Myers Squibb’s own pipeline as RYZ401, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2025First study: phase 1 study in Gastro-enteropancreatic neuroendocrine tumorFirst studyNCT07165132 · 104 planned · United States, Canada

Ahead

  1. Feb 2027Primary completion: phase 1 study in Gastro-enteropancreatic neuroendocrine tumorNCT07165132

TargetBeta

“A radioconjugate consisting of a somatostatin receptor 2 (SSTR2)-targeting moiety labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration, actinium Ac 225 SSTR2-targeted agent RYZ401 targets and binds to SSTR2 overexpressed on many…”NCIt, read by Claude
“A radioconjugate consisting of a somatostatin receptor 2 (SSTR2)-targeting moiety ”NCIt, by rule

Other programs on SSTR2

ProgramCompanyFurthest phaseStudies
OctreotideruleNovartisphase 436
PaltusotineruleVertex Pharmaceuticalsphase 39
actinium AC-225 dotatateBristol-Myers Squibbphase 33
SSTR2-targeting Non-peptide Drug Conjugate CRN09682ruleVertex Pharmaceuticalsphase 21
NTQ6179Sino Biopharmaceuticalphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07165132Gastro-enteropancreatic neuroendocrine tumor · United States, Canada1RecruitingFeb 2027104

How it is read

Names in the registry

  • “RYZ401”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.